Cannabidiol

Generic Name: Cannabidiol

Brand Names: Epidiolex, Sativex, Epidyolex

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 13956-29-1

Unique Ingredient Identifier: 19GBJ60SN5

Background: Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...

Indication: When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...

Associated Conditions: Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain

Associated Therapies: -

Clinical Trials

A Phase 2a Study to Evaluate the Safety and Efficacy of Cannabidiol Only as Maintenance Therapy and Steroid Sparing in Patients With Stable Autoimmune Hepatitis

Phase 2

Terminated

Conditions: Autoimmune Hepatitis

Interventions: Drug: Cannabidiol

First Posted Date: 2019-10-16

Last Posted Date: 2020-06-16

Lead Sponsor: Stero Biotechs Ltd.

Target Recruit Count: 2

Registration Number: NCT04129489

Locations: 🇮🇱
Belinson Medical Center, Petach Tikva, Israel

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

Phase 2

Recruiting

Conditions: Dual Diagnosis

Interventions: Drug: Cannabidiol
Drug: Risperidone

First Posted Date: 2019-09-26

Last Posted Date: 2024-12-12

Lead Sponsor: Lone Baandrup

Target Recruit Count: 64

Registration Number: NCT04105231

Locations: 🇩🇰
Center for Neuropsychiatric Schizophrenia Research, Glostrup, Denmark

The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy

Phase 2

Completed

Conditions: Diabetic Neuropathies

Interventions: Drug: CBD

First Posted Date: 2019-09-13

Last Posted Date: 2019-12-11

Lead Sponsor: Pure Green

Target Recruit Count: 32

Registration Number: NCT04088929

Locations: 🇺🇸
Dr. Nakadar's Office, Sterling Heights, Michigan, United States

Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults

Not Applicable

Completed

Conditions: Opioid-induced Hyperalgesia
Acute Nociceptive Pain
Hyperalgesia
Allodynia

Interventions: Drug: CBD
Drug: Placebo
Drug: Remifentanil

First Posted Date: 2019-08-16

Last Posted Date: 2020-10-19

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 21

Registration Number: NCT04059978

Locations: 🇨🇭
Department of Anaesthesiology, University Hospital of Basel (USB), Basel, Switzerland

Mechanisms of CBD for Chronic Pain

Early Phase 1

Recruiting

Conditions: Chronic Pain

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2019-08-05

Last Posted Date: 2024-04-26

Lead Sponsor: University of Utah

Target Recruit Count: 52

Registration Number: NCT04044729

Locations: 🇺🇸
University Of Utah, Salt Lake City, Utah, United States

PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

Phase 2

Recruiting

Conditions: Chronic Pain

Interventions: Drug: Cannabidiol
Drug: Placebo

First Posted Date: 2019-06-13

Last Posted Date: 2024-10-04

Lead Sponsor: Staci Gruber, Ph.D.

Target Recruit Count: 25

Registration Number: NCT03984565

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia

Phase 2

Completed

Conditions: Gastroparesis
Dyspepsia

Interventions: Other: placebo
Drug: Cannabidiol

First Posted Date: 2019-05-07

Last Posted Date: 2024-02-13

Lead Sponsor: Mayo Clinic

Target Recruit Count: 92

Registration Number: NCT03941288

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Cannabidiol for Alcohol Use Disorder

Phase 1

Withdrawn

Conditions: Alcohol Use Disorder

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2019-04-05

Last Posted Date: 2019-10-11

Lead Sponsor: Medical University of South Carolina

Registration Number: NCT03904849

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain

Phase 4

Terminated

Conditions: Back Pain, Low

Interventions: Drug: Cannabidiol

First Posted Date: 2019-03-27

Last Posted Date: 2022-05-04

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 7

Registration Number: NCT03891264

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

Phase 2

Conditions: Prevention aGVHD

Interventions: Drug: CBD

First Posted Date: 2019-02-15

Last Posted Date: 2021-09-01

Lead Sponsor: Kalytera Therapeutics Israel, Ltd.

Target Recruit Count: 36

Registration Number: NCT03840512

Locations: 🇦🇺
St Vincent's Hospital Sydney - The Kinghorn Cancer Centre, Sydney, Australia
🇮🇱
Davidof Cancer Center, Beilinson hospital, Rabin medical center, Petach Tikva, Israel
🇮🇱
Hadassah Medical Center - Bone Marrow Transplantation Department, Cancer Immunotherapy and Immunobiology Research Center, Jerusalem, Israel

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy